Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00255099
Status:
COMPLETED
Last Update Posted:
2011-06-15
First Post:
2005-11-15
Brief Title:
TMC125-C216 A Phase III Study to Investigate the Efficacy Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen Including TMC114Ritonavir and an Investigator-selected Optimized Background in HIV-1 Infected Patients With Limited to no Treatment Options
Sponsor:
Organization:
Tibotec Pharmaceuticals Ireland
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
593
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: